• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Werewolf Therapeutics Inc (NQ: HOWL )

    2.200 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Werewolf Therapeutics Inc

    < Previous 1 2 Next >
    Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
    PREDATOR protein engineering technology allows for the expansion of INDUKINE™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel... 
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124
    Virtual event to be held on Monday, September 18, 2023, at 10:00 am ET 
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics to Participate in Upcoming Investor Conferences
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics to Present at the Jefferies Healthcare Conference
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
    From Werewolf Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.